19 December 2025
19 December 2025
At least five state committees in the US are exploring ways to enact independent measures to improve drug affordability.
Poised to become law, the BIOSECURE Act will have ramifications for certain US-China pharmaceutical relationships.
Depo Provera’s label change comes amidst a flurry of over 2,000 lawsuits from women alleging that the contraceptive caused their meningiomas.
Lilly has now submitted a new drug application (NDA) for orforglipron to the FDA for use in adults with obesity.
The approval is supported by results from the Phase III PALOMA-3 study.
Takeda’s oral PsO candidate met its primary and secondary endpoints in two Phase III trials.
The commission brings together experts, clinicians, patient advocates, and regulators to advise the MHRA on the AI regulation.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
